Literature DB >> 11132605

ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats.

B Hocher1, I George, F Diekmann, R Zart, J Rebstock, A Schwarz, C Thöne-Reineke, H H Neumayer, C Bauer.   

Abstract

BACKGROUND: In two kidney-one clip renovascular hypertension (2K1C), blood flow is reduced in the clipped kidney leading to ischaemia. The non-clipped kidney is characterized by increased shear stress. Circulating Ang II is elevated. All these factors are stimuli of the paracrine renal endothelin system. Indeed, we demonstrated an activation of the renal endothelin system in the 2K1C rat model.
METHODS: We analysed the effects of chronic treatment with the ETA receptor antagonist BQ-123 on blood pressure, heart rate, plasma renin activity, and on the progression of glomerulosclerosis, interstitial fibrosis and vascular remodeling in the clipped and non-clipped kidney.
RESULTS: Long-term treatment with BQ-123 led to a fibrotic atrophy of the clipped kidney characterized by a significantly reduced weight of the clipped kidney compared to the clipped kidney of the placebo-treated group. Computer-aided image analysis revealed a markedly enhanced interstitial fibrosis of these clipped kidneys after long-term ETA blockade. The effects of ETA receptor antagonists on the non-clipped kidney were less pronounced. Neither blood pressure nor plasma renin activity were significantly altered by BQ-123 treatment.
CONCLUSIONS: The present study indicates that long-term blockade of the activated endothelin system in the clipped kidney of rats with renovascular hypertension using an ETA receptor antagonist led to a fibrotic atrophy of the clipped kidney.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11132605     DOI: 10.1097/00004872-200018120-00015

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.

Authors:  Philipp Kalk; Michael Godes; Katharina Relle; Christiane Rothkegel; Andreas Hucke; Johannes-Peter Stasch; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

2.  The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.

Authors:  P Kalk; B Eggert; K Relle; M Godes; S Heiden; Y Sharkovska; Y Fischer; D Ziegler; G-W Bielenberg; B Hocher
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

3.  Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.

Authors:  Sandra Geschka; Axel Kretschmer; Yuliya Sharkovska; Oleg V Evgenov; Bettina Lawrenz; Andreas Hucke; Berthold Hocher; Johannes-Peter Stasch
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

4.  Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.

Authors:  Linda S Hoffmann; Axel Kretschmer; Bettina Lawrenz; Berthold Hocher; Johannes-Peter Stasch
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  Establishment and evaluation of a reversible two-kidney, one-clip renovascular hypertensive rat model.

Authors:  Li-Qiang Li; Jian Zhang; Rong Wang; Jian-Xin Li; Yong-Quan Gu
Journal:  Exp Ther Med       Date:  2017-04-26       Impact factor: 2.447

6.  Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.

Authors:  Ina M Ott; Markus L Alter; Karoline von Websky; Axel Kretschmer; Oleg Tsuprykov; Yuliya Sharkovska; Katharina Krause-Relle; Jens Raila; Andrea Henze; Johannes-Peter Stasch; Berthold Hocher
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

7.  Renal phenotype of ET-1 transgenic mice is modulated by androgens.

Authors:  P Kalk; C Thöne-Reineke; A Schwarz; M Godes; C Bauer; T Pfab; B Hocher
Journal:  Eur J Med Res       Date:  2009       Impact factor: 2.175

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.